{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:32:48Z","timestamp":1791405168993,"version":"4.3.3"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,23]],"date-time":"2021-02-23T00:00:00Z","timestamp":1614038400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,2,23]],"date-time":"2021-02-23T00:00:00Z","timestamp":1614038400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Osteoporos"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s11657-021-00899-5","type":"journal-article","created":{"date-parts":[[2021,2,23]],"date-time":"2021-02-23T19:28:05Z","timestamp":1614108485000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Effects of denosumab on rheumatic diseases and refractory glucocorticoid-induced osteoporosis: a prospective study"],"prefix":"10.1007","volume":"16","author":[{"given":"Takaaki","family":"Ishida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuzo","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youhei","family":"Fujiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichiro","family":"Hata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Kotani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0065-929X","authenticated-orcid":false,"given":"Tohru","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,23]]},"reference":[{"key":"899_CR1","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1097\/BOR.0000000000000608","volume":"31","author":"G Adami","year":"2019","unstructured":"Adami G, Saag KG (2019) Glucocorticoid-induced osteoporosis update. Curr Opin Rheumatol 31:388\u2013393","journal-title":"Curr Opin Rheumatol"},{"key":"899_CR2","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1007\/s00198-019-04906-x","volume":"30","author":"G Adami","year":"2019","unstructured":"Adami G, Saag KG (2019) Glucocorticoid-induced osteoporosis: 2019 Concise Clinical Review. Osteoporos Int 30:1145\u20131156","journal-title":"Osteoporos Int"},{"key":"899_CR3","doi-asserted-by":"publisher","first-page":"3224","DOI":"10.1002\/art.11283","volume":"48","author":"TP Van Staa","year":"2003","unstructured":"Van Staa TP, Laan RF, Barton IP, Cohen S, Reid DM, Cooper C (2003) Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum 48:3224\u20133229","journal-title":"Arthritis Rheum"},{"key":"899_CR4","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1002\/art.40137","volume":"69","author":"L Buckley","year":"2017","unstructured":"Buckley L, Guyatt G, Fink HA, Michael C, Jennifer G, Karen EH et al (2017) 2017 American College of Rheumatology Guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheumatol 69:1521\u20131537","journal-title":"Arthritis Rheumatol"},{"key":"899_CR5","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s11657-017-0324-5","volume":"12","author":"J Compston","year":"2017","unstructured":"Compston J, Cooper A, Cooper C, Gittoes N, Gregson C, Harvey N et al (2017) UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos 12:43","journal-title":"Arch Osteoporos"},{"key":"899_CR6","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s00774-014-0586-6","volume":"32","author":"Y Suzuki","year":"2014","unstructured":"Suzuki Y, Nawata H, Soen S, Fujiwara S, Nakayama H, Tanaka I, Ozono K, Sagawa A, Takayanagi R, Tanaka H, Miki T, Masunari N, Tanaka Y (2014) Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research: 2014 update. J Bone Miner Metab 32:337\u2013350","journal-title":"J Bone Miner Metab"},{"key":"899_CR7","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1056\/NEJMoa030897","volume":"350","author":"HG Bone","year":"2004","unstructured":"Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, Rodriguez-Portales JA, Downs RW, Gupta J, Santora AC, Liberman UA (2004) Ten years\u2019 experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350:1189\u20131199","journal-title":"N Engl J Med"},{"key":"899_CR8","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1007\/s00198-014-2619-3","volume":"25","author":"E Cairoli","year":"2014","unstructured":"Cairoli E, Eller-Vainicher C, Ulivieri FM, Zhukouskaya VV, Palmieri S, Morelli V, Beck-Peccoz P, Chiodini I (2014) Factors associated with bisphosphonate treatment failure in postmenopausal women with primary osteoporosis. Osteoporos Int 25:1401\u20131410","journal-title":"Osteoporos Int"},{"key":"899_CR9","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1002\/jbmr.533","volume":"27","author":"JS Sampalis","year":"2012","unstructured":"Sampalis JS, Adachi JD, Rampakakis E, Vaillancourt J, Karellis A, Kindundu C (2012) Long-term impact of adherence to oral bisphosphonates on osteoporotic fracture incidence. J Bone Miner Res 27:202\u2013210","journal-title":"J Bone Miner Res"},{"key":"899_CR10","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1359\/JBMR.040305","volume":"19","author":"PJ Bekker","year":"2004","unstructured":"Bekker PJ, Holloway DL, Rasmussen AS, Murphy R, Martin SW, Leese PT, Holmes GB, Dunstan CR, DePaoli AM (2004) A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 19:1059\u20131066","journal-title":"J Bone Miner Res"},{"key":"899_CR11","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","volume":"5","author":"HG Bone","year":"2017","unstructured":"Bone HG, Wagman RB, Brandi ML, Brown JP, Chapurlat R, Cummings SR, Czerwi\u0144ski E, Fahrleitner-Pammer A, Kendler DL, Lippuner K, Reginster JY, Roux C, Malouf J, Bradley MN, Daizadeh NS, Wang A, Dakin P, Pannacciulli N, Dempster DW, Papapoulos S (2017) 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol 5:513\u2013523","journal-title":"Lancet Diabetes Endocrinol"},{"key":"899_CR12","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1210\/jc.2013-4175","volume":"99","author":"T Nakamura","year":"2014","unstructured":"Nakamura T, Matsumoto T, Sugimoto T, Hosoi T, Miki T, Gorai I, Yoshikawa H, Tanaka Y, Tanaka S, Sone T, Nakano T, Ito M, Matsui S, Yoneda T, Takami H, Watanabe K, Osakabe T, Shiraki M, Fukunaga M (2014) Clinical Trials Express: fracture risk reduction with denosumab in Japanese postmenopausal women and men with osteoporosis: denosumab fracture intervention randomized placebo controlled trial (DIRECT). J Clin Endocrinol Metab 99:2599\u20132607","journal-title":"J Clin Endocrinol Metab"},{"key":"899_CR13","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1359\/jbmr.0809010","volume":"24","author":"JP Brown","year":"2009","unstructured":"Brown JP, Prince RL, Deal C, Recker RR, Kiel DP, de Gregorio LH, Hadji P, Hofbauer LC, \u00c1lvaro-Gracia JM, Wang H, Austin M, Wagman RB, Newmark R, Libanati C, San Martin J, Bone HG (2009) Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res 24:153\u2013161","journal-title":"J Bone Miner Res"},{"key":"899_CR14","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/S2213-8587(18)30075-5","volume":"6","author":"KG Saag","year":"2018","unstructured":"Saag KG, Wagman RB, Geusens P, Adachi JD, Messina O, Emkey R et al (2018) Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomized, double-blind, active-controlled, double-dummy, non-inferiority study. Lancet Diabetes Endocrinol 6:445\u2013454","journal-title":"Lancet Diabetes Endocrinol"},{"key":"899_CR15","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1359\/JBMR.041233","volume":"20","author":"S Sivagurunathan","year":"2005","unstructured":"Sivagurunathan S, Muir MM, Brennan TC, Seale JP, Mason RS (2005) Influence of glucocorticoids on human osteoclast generation and activity. J Bone Miner Res 20:390\u2013398","journal-title":"J Bone Miner Res"},{"key":"899_CR16","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s11657-017-0336-1","volume":"12","author":"S Ishiguro","year":"2017","unstructured":"Ishiguro S, Ito K, Nakagawa S, Hataji O, Sudo A (2017) The clinical benefits of denosumab for prophylaxis of steroid-induced osteoporosis in patients with pulmonary disease. Arch Osteoporos 12:44","journal-title":"Arch Osteoporos"},{"key":"899_CR17","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s00198-016-3764-7","volume":"28","author":"M Kamimura","year":"2017","unstructured":"Kamimura M, Nakamura Y, Ikegami S, Uchiyama S, Kato H, Taguchi A (2017) Significant improvement of bone mineral density and bone turnover markers by denosumab therapy in bisphosphonate-unresponsive patients. Osteoporos Int 28:559\u2013566","journal-title":"Osteoporos Int"},{"key":"899_CR18","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s002239900713","volume":"65","author":"S Gonnelli","year":"1999","unstructured":"Gonnelli S, Cepollaro C, Pondrelli C, Martini S, Montagnani A, Monaco R, Gennari C (1999) Bone turnover and the response to alendronate treatment in postmenopausal osteoporosis. Calcif Tissue Int 65:359\u2013364","journal-title":"Calcif Tissue Int"},{"key":"899_CR19","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1007\/s001980170020","volume":"12","author":"NH Bjarnason","year":"2001","unstructured":"Bjarnason NH, Sarkar S, Duong T, Mitlak B, Delmas PD, Christiansen C (2001) Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis. Osteoporos Int 12:922\u2013930","journal-title":"Osteoporos Int"},{"key":"899_CR20","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1002\/jbmr.251","volume":"26","author":"R Eastell","year":"2011","unstructured":"Eastell R, Christiansen C, Grauer A, Kutilek S, Libanati C, McClung MR et al (2011) Effects of denosumab on bone turnover markers in postmenopausal osteoporosis. J Bone Miner Res 26:530\u2013537","journal-title":"J Bone Miner Res"},{"key":"899_CR21","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.bone.2016.11.009","volume":"95","author":"JN Tsai","year":"2017","unstructured":"Tsai JN, Burnett-Bowie SM, Lee H, Leder BZ (2017) Relationship between bone turnover and density with teriparatide, denosumab or both in women in the DATA study. Bone 95:20\u201325","journal-title":"Bone"}],"container-title":["Archives of Osteoporosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11657-021-00899-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11657-021-00899-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11657-021-00899-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T15:38:05Z","timestamp":1642088285000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11657-021-00899-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,23]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["899"],"URL":"https:\/\/doi.org\/10.1007\/s11657-021-00899-5","relation":{},"ISSN":["1862-3522","1862-3514"],"issn-type":[{"value":"1862-3522","type":"print"},{"value":"1862-3514","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,23]]},"assertion":[{"value":"6 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}],"article-number":"39"}}